CMTx Biotech Inc.
CMTx Biotech, Inc. is a clinical-stage biotechnology company focused on commercializing proprietary small-molecule therapeutics for rare, orphan, and pandemic diseases. With a proven safety record and accelerated development pipeline, the company aims to improve critical patient outcomes through innovative drug development. Their lead candidate has completed IND-enabling studies and has demonstrated safety in human trials for various indications, expediting the path to clinical trials and market approval. The management team brings extensive experience in drug development, commercialization, licensing, and technology transfer.
Industries
Nr. of Employees
small (1-50)
Products
Chemically modified tetracycline derivative (lead small-molecule candidate)
A non-antimicrobial, chemically modified tetracycline-class small-molecule candidate developed as an anti-inflammatory and MMP-inhibiting therapeutic for indications including acute lung injury, ARDS, sepsis complications, and potential pandemic respiratory disease treatment.
Chemically modified tetracycline derivative (lead small-molecule candidate)
A non-antimicrobial, chemically modified tetracycline-class small-molecule candidate developed as an anti-inflammatory and MMP-inhibiting therapeutic for indications including acute lung injury, ARDS, sepsis complications, and potential pandemic respiratory disease treatment.
Services
Design and execution of animal studies to assess efficacy of anti-inflammatory small molecules in ARDS, VILI, and sepsis-relevant endpoints.
Preparation of preclinical packages and regulatory briefing documents to support pre-IND meetings and IND submissions.
Network- and data-driven computational analyses to prioritize existing small molecules for new indications.
Negotiation and execution of licensing arrangements and commercial partnerships to advance therapeutic candidates.
Design and execution of animal studies to assess efficacy of anti-inflammatory small molecules in ARDS, VILI, and sepsis-relevant endpoints.
Preparation of preclinical packages and regulatory briefing documents to support pre-IND meetings and IND submissions.
Network- and data-driven computational analyses to prioritize existing small molecules for new indications.
Negotiation and execution of licensing arrangements and commercial partnerships to advance therapeutic candidates.
Expertise Areas
- Clinical trial management (Phase I/II)
- Preclinical models of ARDS and sepsis
- Small-molecule therapeutic development
- Drug repurposing and computational screening
Key Technologies
- In silico drug repurposing / computational network analysis
- Clinically relevant animal models for lung injury and sepsis
- Matrix metalloproteinase (MMP) inhibition assays
- Cytokine and biomarker assays
News & Updates
CMTx Biotech announced the execution of an exclusive license agreement with Galderma, expanding its commercial reach and development opportunities.
CMTx Biotech received a $315,000 grant from the National Center for Advancing Translational Sciences (NCATS) to support its research and development efforts.
CMTx Biotech is adapting its development pipeline and focus to address urgent needs arising from the COVID-19 pandemic.
CMTx Biotech submitted a pre-IND (Investigational New Drug) meeting request and briefing package, advancing its lead candidate toward clinical trials.
A computational study highlights incyclinide (COL-3) as a potential repurposed drug for treating COVID-19-related lung injury.
An independent study examines the potential of incyclinide (COL-3) for COVID-19 treatment, supporting its repurposing for pandemic response.
CMTx Biotech announced the execution of an exclusive license agreement with Galderma, expanding its commercial reach and development opportunities.
CMTx Biotech received a $315,000 grant from the National Center for Advancing Translational Sciences (NCATS) to support its research and development efforts.
CMTx Biotech is adapting its development pipeline and focus to address urgent needs arising from the COVID-19 pandemic.
CMTx Biotech submitted a pre-IND (Investigational New Drug) meeting request and briefing package, advancing its lead candidate toward clinical trials.
A computational study highlights incyclinide (COL-3) as a potential repurposed drug for treating COVID-19-related lung injury.
An independent study examines the potential of incyclinide (COL-3) for COVID-19 treatment, supporting its repurposing for pandemic response.